|
|
|
| Research progresses of biomarkers of glioblastoma multiforme |
| XIONG Zhongkui1 LANG Juan2 WANG Siben1 |
1.Department of Oncology Radiotherapy, Shaoxing Second Hospital of Zhejiang Province, Zhejiang Province, Shaoxing 312000, China;
2.Department of Pathology, Shaoxing People′s Hospital of Zhejiang Province, Zhejiang Province, Shaoxing 312000, China |
|
|
|
Abstract Biomarkers of Glioblastoma multiforme (GBM) plays an important role in disease diagnosis, efficacy prediction and prognosis. There are four types of biomarkers for GBM: classical biomarkers, circulating biomarkers, gene tags and others. In view of the high invasiveness and complexity of GBM, there is an urgent to conduct in-depth clinical studies on non-invasive biomarkers that can be used for prognosis and prediction, especially for early diagnosis.
|
|
|
|
|
|
[1] Wang J，Su HK，Zhao HF，et al. Progress in the application of molecular biomarkers in gliomas [J]. Biochem Biophys Res Commun，2015，465（1）：1-4.
[2] Montano N，Cenci T，Martini M，et al. Expression of EGFRvⅢ in glioblastoma：prognostic significance revisited [J]. Neoplasia，2011，13（12）：1113-1121.
[3] Chen R，Cohen AL，Colman H. Targeted Therapeutics in Patients With High-Grade Gliomas：Past，Present，and Future [J]. Curr Treat Options Oncol，2016，17（8）：42.
[4] Alifieris C，Trafalis DT. Glioblastoma multiforme：Pathogenesis and treatment [J]. Pharmacol Ther，2015，152：63-82.
[5] Li X，Wu C，Chen N，et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma [J]. Oncotarget，2016，7（22）：33440-33450.
[6] Sami A，Karsy M. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma：novel therapeutic agents and advances in understanding [J]. Tumour Biol，2013，34（4）：1991-2002.
[7] Singh VY，Chacko G，Chacko AG，et al. Fluorescence in situ hybridization for 1p，19q status in a cohort of glial neoplasms [J]. Neurol India，2014，62（1）：32-36.
[8] Sabha N，Knobbe CB，Maganti M，et al. Analysis of IDH mutation，1p/19q deletion，and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas [J]. Neuro Oncol，2014，16（7）：914-923.
[9] Qin JJ，Liu ZX，Wang JM，et al. Prognostic factors influencing clinical outcomes of malignant glioblastoma multiforme：clinical，immunophenotypic，and fluorescence in situ hybridization findings for 1p19q in 816 chinese cases [J]. Asian Pac J Cancer Prev，2015，16（3）：971-977.
[10] Weller M，Pfister SM，Wick W，et al. Molecular neuro-oncology in clinical practice：a new horizon [J]. Lancet Oncol，2013，14（9）：e370-379.
[11] Beiko J，Suki D，Hess KR，et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection [J]. Neuro Oncol，2014，16（1）：81-91.
[12] Weller M，Tabatabai G，Kastner B，et al. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma：The DIRECTOR Trial [J]. Clin Cancer Res，2015，21（9）：2057-2064.
[13] Tan SK，Pastori C，Penas C，et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme [J]. Mol Cancer，2018，17（1）：74.
[14] Li HY，Li YM，Li Y，et al. Circulating microRNA-137 is a potential biomarker for human glioblastoma [J]. Eur Rev Med Pharmacol Sci，2016，20（17）：3599-3604.
[15] Wang ZQ，Zhang MY，Deng ML，et al. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma [J]. PLoS One，2017，12（9）：e0184969.
[16] Yang Q，Wang R，Wei B，et al. Candidate Biomarkers and Molecular Mechanism Investigation for Glioblastoma Multiforme Utilizing WGCNA [J]. Biomed Res Int，2018， 2018：4246703.
[17] Osti D，Del Bene M，Rappa G，et al. Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients [J]. Clin Cancer Res，2019，25（1）：266-276.
[18] Krol I，Castro-Giner F，Maurer M，et al. Detection of circulating tumour cell clusters in human glioblastoma [J]. Br J Cancer，2018，119（4）：487-491.
[19] Chen G，Cao Y，Zhang L，et al. Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas [J]. Oncotarget，2017，8（40）：67744-67753.
[20] Fatai AA，Gamieldien J. A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer [J]. BMC Cancer，2018，18（1）：377.
[21] Zhang Y，Xu J，Zhu X. A 63 signature genes prediction system is effective for glioblastoma prognosis [J]. Int J Mol Med，2018，41（4）：2070-2078.
[22] Huang SP，Chang YC，Low QH，et al. BICD1 expression，as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas [J]. Oncotarget，2017，8（69）：113766-113791.
[23] Wang D，Berglund AE，Kenchappa RS，et al. BIRC3 is a biomarker of mesenchymal habitat of glioblastoma，and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats [J]. Sci Rep，2017，7（1）：9350.
[24] Guo RM，Zhao CB，Li P，et al. Overexpression of CLEC18B Associates With the Proliferation，Migration，and Prognosis of Glioblastoma [J]. ASN Neuro，2018，10：1 759 091 418 781 949.
[25] Cho HR，Jeon H，Park CK，et al. Radiogenomics Profiling for Glioblastoma-related Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis [J]. Sci Rep，2018，8（1）：16022.
[26] Li G，Shen J，Cao J，et al. Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461 [J]. J Exp Clin Cancer Res，2018，37（1）：78.
[27] Cho HR，Jeon H，Park CK，et al. BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients [J]. Sci Rep，2017， 7（1）：17740.
[28] Lehrer S，Rheinstein PH，Rosenzweig KE. Glioblastoma Multiforme：Fewer Tumor Copy Number Segments of the SGK1 Gene Are Associated with Poorer Survival [J]. Cancer Genomics Proteomics，2018，15（4）：273-278.
[29] Yu M，Yu S，Xue Y，et al. Over-Expressed FEZF1 Predicts a Poor Prognosis in Glioma and Promotes Glioma Cell Malignant Biological Properties by Regulating Akt-ERK Pathway [J]. J Mol Neurosci，2018，65（4）：411-419. |
|
|
|
